Evernorth and Transcarent Collaborate to Deliver Unmatched Cancer Care, Navigation, and Support Services Starting January 1, 2025 Transcarent, known as the One Place for Health and Care, has been selected to power Evernorth Health Services’ new Oncology Benefit Services program.…
Over 50 Research Studies by IVI RMA North America Set to Advance Infertility Care at ASRM 2024 IVI RMA North America, which encompasses Reproductive Medicine Associates and Boston IVF, will showcase more than 50 groundbreaking infertility research studies at the…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative therapies for seizure disorders, has shared new data from its Phase 3 RAISE trial on intravenous (IV) ganaxolone for refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS)…
Shimadzu Corporation, Eisai Co., Ltd., Oita University, and the Usuki City Medical Association have demonstrated that blood biomarkers can effectively predict amyloid beta (Aβ) accumulation in the brain, a major factor linked to Alzheimer’s disease. Their findings come from a…
Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for treating seriously ill adult patients with Gram-negative (GN) bacterial infections.…
BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM) held in Prague…
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and COVID-19 at IDWeek 2024,…
Etcembly and University of Surrey Launch Study to Transform Cancer Treatment British techbio innovator Etcembly is collaborating with researchers from the University of Surrey to launch a groundbreaking study aimed at revolutionizing cancer treatment. The research will analyze the immune…
STRIDE-8 Study Results Highlight CAPVAXIVE’s Efficacy in Pneumococcal Disease Prevention CAPVAXIVE Demonstrates Strong Immune Response and Coverage Against Major Serotypes RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, presented promising results from the…
ViiV Healthcare Presents Real-World Evidence for Apretude (Cabotegravir Long-Acting) at IDWeek 2024 GSK plc (LSE/NYSE: GSK) has announced that ViiV Healthcare, a global leader in HIV treatment and prevention, has shared new real-world evidence on the effectiveness, adherence, and quality-of-life…
Bayer to Present Latest Research on Menopausal Sleep Disturbances at IMS 2024 Bayer is set to showcase its latest research on menopause symptoms, particularly sleep disturbances, at the 19th World Congress of the International Menopause Society (IMS) from October 19-22,…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 GenSight Biologics (Euronext: SIGHT), a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced new scientific data on its gene therapy, LUMEVOQ®,…